Hepatitis C virus 1b viral factors (core, NS3, and NS5A) and increased risk of hepatocellular carcinoma

Hepatology

Volumn 58, Issue 2, 2013, Pages 491-493

  Sharma, Suresh D ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CORE PROTEIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; PROTEIN KINASE R;

AMINO ACID SEQUENCE; ANTIVIRAL THERAPY; CANCER RISK; EDITORIAL; GENOTYPE; HEPATITIS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; VIRUS CARCINOGENESIS;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84881025896     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26362     Document Type: Editorial

References (21)

1. Sharma SD. Hepatitis C virus: molecular biology & current therapeutic options. Indian J Med Res 2010;131:17-34.
2. Sklan EH, Charuworn P, Pang PS, Glenn JS. Mechanisms of HCV survival in the host. Nat Rev 2009;6:217-227.
3. Gelman MA, Glenn JS. Mixing the right hepatitis C inhibitor cocktail. Trends Mol Med 2010 [Epub ahead of print].
4. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
5. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5a is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011;9:32-45.
6. Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P, et al. Essential role of domain III of nonstructural protein 5a for hepatitis C virus infectious particle assembly. PLoS Pathog 2008;4:e1000035.
7. Nelson DR, Jensen DM, Sulkowski MS, Everson G, Fried MW, Gordon SC, et al. Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat 2012:138302.
8. Yeh MM, Daniel HD, Torbenson M. Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol 2010;23:276-283.
9. Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996;70:4438-4443.
10. Raney KD, Sharma SD, Moustafa IM, Cameron CE. Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem 2010;285:22725-22731.
11. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3t3 cells. J Virol 1995;69:3893-3896.
12. Deng L, Nagano-Fujii M, Tanaka M, Nomura-Takigawa Y, Ikeda M, Kato N, et al. NS3 protein of hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol 2006;87(Pt 6):1703-1713.
13. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366-375.
14. El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, Hotta H. Polymorphisms of the Core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma. Hepatology 2013;58:555-563.
15. Hoffman B, Liu Q. Hepatitis C viral protein translation: mechanisms and implications in developing antivirals. Liver Int 2011;31:1449-1467.
16. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 2007;46:1357-1364.
17. Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, et al. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol 2010;82:41-48.
18. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J Med Virol 2010;82:575-582.
19. Huang L, Hwang J, Sharma SD, Hargittai MR, Chen Y, Arnold JJ, et al. Hepatitis C virus nonstructural protein 5a (NS5a) is an RNA-binding protein. J Biol Chem 2005;280:36417-36428.
20. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005;435:374-379.
21. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5a predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology 2008;48:38-47.